Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin, but evidence about their effectiveness and safety in patients with valvular atrial fibrillation (AF) remains limited.
In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. This data may be used to guide risk–benefit discussions regarding anticoagulant choices for patients with valvular AF.
Please join us for this webinar as the authors discuss the effectiveness and safety of DOACs compared with warfarin in patients with valvular AF.
• Geoffrey Barnes, MD, MSc
• Adam Cuker, MD, MS
• Ghadeer Dawwas, PhD, MSc, MBA
• Arthur Allen, PharmD, CACP
• Diane Wirth, ANP, CACP
Link to article: https://www.acpjournals.org/doi/10.7326/M20-6194
We are pleased to provide enduring accreditation for this webinar!